Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVER4010001 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Everest Medicines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
EVER4010001 + pembrolizumab is a combination regimen for the treatment of advanced solid tumors, currently being evaluated in clinical trials. **EVER4010001** is a highly selective small molecule inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4), developed to target FGF19-FGFR4 signaling, which is implicated in tumor growth and disease progression in certain cancers. **Pembrolizumab**, marketed as Keytruda, is a monoclonal antibody that inhibits the programmed death-1 (PD-1) immune checkpoint, enhancing T-cell mediated immune responses against tumors. The combination is designed to use dual targeting of oncogenic signaling (FGFR4) and immune checkpoint inhibition (PD-1) to achieve enhanced anti-tumor efficacy[1][3][5][7].
- Brand names
- Keytruda
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on EVER4010001 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVER4010001 + pembrolizumab.